Buy LUCD by Dec 12, 2026.

EDIT: I didn't think I needed to state this, but this is Lucid the diagnostics company, maker of EsoGuard, NOT Lucid the EV company. 1) They think multi-cancer early detection (MCED) blood tests cover esophageal cancer. These tests do detect stage 3-4 esophageal cancer with decent sensitivity (94-100%), but by then it’s too late. EsoGuard enables a total cure by identifying a precancerous condition called Barrett’s esophagus (BE). At this stage, sensitivity of MCEDs is <12.5%. [Source](https://www.annalsofoncology.org/article/S0923-7534(21)02046-9/fulltext) 2) EsoGuard seems …